PRIOR ART METHOD A



FIG. 1a


PRIOR ART METHOD B
(iii)
B
BIOTINYLATED ALLERGEN
+
(
IgE
(i)
+
X
)
IgE
B
X
B
* ADD SOLID PHASE
(ii)
* ADD STREPTAVIDIN LITE REAGENT
(iv)
* INCUBATE
IgE
B
X
B
* WASH
IgE
B
* READ FLASH

FIG. 1b


METHOD OF THE INVENTION (METHOD 1)
(ii)
(i)
SOLID PHASE
IgE
X
* INCUBATE
* WASH
IgE
(iii)
B
* ADD BIOTINYLATED ALLERGEN
B
IgE
B
(iv)
* ADD STREPTAVIDIN LITE REAGENT
IgE
B
B
* WASH
IgE
B
* READ FLASH

FIG. 2a


METHOD OF THE INVENTION
(ii)
(i)
+
(
+
)
IgE
X
SOLID PHASE
* INCUBATE
* WASH
IgE
(iii)
B
* ADD BIOTINYLATED ALLERGEN
(iv)
* ADD STREPTAVIDIN LITE REAGENT
B
IgE
B
* WASH
B
IgE
* READ FLASH

FIG. 2b

METHOD OF THE INVENTION.



FIG. 2c


SUBMETHOD OF THE INVENTION
(iii)
B
BIOTINYLATED ALLERGEN
+
(
IgE
(i)
+
X
)
B
IgE
B
X
(ii)
* ADD SOLID PHRASE
* INCUBATE
* WASH
B
IgE
(iv)
* ADD STREPTAVIDIN LITE REAGENT
B
IgE
* WASH
B
IgE
* READ FLASH

FIG. 3a

SUBMETHOD OF THE INVENTION



FIG. 3b

SUBMETHOD OF THE INVENTION



FIG. 3c


SIGNAL/BACKGROUND
PRIOR ART METHOD B
1000
100
10
1
1
10
100
1000
BIRCH SPECIFIC IgE CONCENTRATION
SU/ml
STANDARD CURVE
SINGLE PATIENTS

FIG. 4


SIGNAL/BACKGROUND
METHOD 1
100
10
1
1
10
100
1000
BIRCH SPECIFIC IgE CONCENTRATION
SU/ml
STANDARD CURVE
SINGLE PATIENTS

FIG. 5


SIGNAL/BACKGROUND
SUBMETHOD 1
100
10
1
1
10
100
1000
BIRCH SPECIFIC IgE CONCENTRATION
SU/ml
STANDARD CURVE
SINGLE PATIENTS

FIG. 6


% RECOVERY
200
180
160
140
120
100
80
60
40
20
1
0,000
0,001
0,010
0,100
RELATIVE TITER OF RABBIT POLYCLONAL ANTI-BETULA VERRUCOSA
SUBMETHOD 1
METHOD 1
PRIOR ART METHOD B

FIG. 7


% RECOVERY
700
600
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
DILUTION FACTOR, SAV SAMPLE #1
METHOD 1
PRIOR ART METHOD B

FIG. 8


% RECOVERY
700
600
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
DILUTION FACTOR, SAV SAMPLE #2
METHOD 1
PRIOR ART METHOD B

FIG. 9


% RECOVERY
700
600
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
DILUTION FACTOR, SAV SAMPLE #3
METHOD 1
PRIOR ART METHOD B

FIG. 10


% RECOVERY
700
600
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
DILUTION FACTOR, SAV SAMPLE #4
METHOD 1
PRIOR ART METHOD B

FIG. 11


% RECOVERY
700
600
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
DILUTION FACTOR, SERUM POOL
METHOD 1
PRIOR ART METHOD B

FIG. 12


SPECIFIC IgE DETERMINED BY PRIOR ART METHOD B
TIME 0
TIME 6
TIME 12
NS
RELATIVE RESPONSE
1000
100
10
1
ACTIVE
PLACEBO

FIG. 13


SPECIFIC IgE DETERMINED BY PRIOR ART METHOD B
TIME 0
TIME 6
TIME 12
NS
RELATIVE RESPONSE
1000
100
10
1
ACTIVE
PLACEBO

FIG. 14


RATIO BETWEEN SPECIFIC IgE DETERMINED BY PRIOR ART METHOD B AND METHOD 1
TIME 0
NS
TIME 6
Pc=0.02224
TIME 12
Pc=0.00781
RATIO
0
1
2
3
4
ACTIVE
PLACEBO

FIG. 15

EFFECT
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
LT_S0_0
LT_S6_0
LT_S12_0
LT_S24_0
10_300
87_300
25_300
06_100
11_100
13_100
58_100
20_300
61_300
24_100
27_300
36_300
29_100
76_300
77_100
71_100
34_100

FIG. 16


NO EFFECT
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
−0.1
−0.2
LT_S0_0
LT_S6_0
LT_S12_0
LT_S24_0
18_0
60_0
31_0
43_0
49_0
53_0
88_0
73_0
37_0

FIG. 17


DOUBTFUL
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
LT_S0_0
LT_S6_0
LT_S12_0
LT_S24_0
02_300
42_300
14_0
32_0
40_0
59_0
63_0
55_0
46_0

FIG. 18

DOSE-RESPONSE RELATION OF THE EFFECT PARAMETER
M_300
M_100
M_10
M_0
<LN(TI/SI)-LN(TO/SO)>
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
-0.1
5
10
15
20
25
MONTH

FIG. 19


EFFECT
NOEFFEC
MEAN EFFECT
MONTH
<LN(TI/SI)-LN(T0/S0)>+-95%CL
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
-0.1
5
10
15
20
25

FIG. 20


EFFECT: INDIVIDUAL PATIENTS
LN(TI/SI)-LN(TO/SO)
MONTH
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
5
10
15
20
25
87_300
76_300
29_100
71_100
41_10
10_300
25_300
30_300
27_300
36_300
74_300
08_100
11_100
13_100
58_100
24_100
69_100
54_10
19_10

FIG. 21

NO EFFECT: INDIVIDUAL PATIENTS
LN(TISI)-LN(TO/SO)
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
MONTH
5
10
15
20
25
02_300
20_300
42_300
15_100
47_10
50_10
33_10
64_10
62_10
14_0
18_0
32_0
40_0
59_0
60_0
63_0
55_0
46_0
28_10
65_10
68_10
17_10
31_0
43_0
49_0
53_0
88_0
73_0

FIG. 22